The ultimate goal of precision medicine is to use population-based molecular, clinical and other data to make individually tailored clinical decisions for patients, although the path to achieving this goal is not entirely clear. A new study shows how knowledge banks of patient data can be used to make individual treatment decisions in acute myeloid leukemia.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Exploring the OncoGenomic Landscape of cancer
Genome Medicine Open Access 03 August 2018
-
Precision therapy for acute myeloid leukemia
Journal of Hematology & Oncology Open Access 05 January 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gerstung, M. et al. Nat. Genet. 49, 332–340 (2017).
Marx, V. Nature 524, 503–505 (2015).
Collins, F.S. & Varmus, H. N. Engl. J. Med. 372, 793–795 (2015).
The Global Alliance for Genomics and Health. Science 352, 1278–1280 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Biankin, A. The road to precision oncology. Nat Genet 49, 320–321 (2017). https://doi.org/10.1038/ng.3796
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3796
This article is cited by
-
Precision therapy for acute myeloid leukemia
Journal of Hematology & Oncology (2018)
-
Exploring the OncoGenomic Landscape of cancer
Genome Medicine (2018)